英格兰、威尔士和北爱尔兰第一次和第二次COVID-19爆发期间中心血液透析患者结局的比较:英国肾脏登记分析

M. Savino, S. Santhakumaran, C. Currie, B. Onggo, Katharine M Evans, J. Medcalf, D. Nitsch, R. Steenkamp
{"title":"英格兰、威尔士和北爱尔兰第一次和第二次COVID-19爆发期间中心血液透析患者结局的比较:英国肾脏登记分析","authors":"M. Savino, S. Santhakumaran, C. Currie, B. Onggo, Katharine M Evans, J. Medcalf, D. Nitsch, R. Steenkamp","doi":"10.1159/000523731","DOIUrl":null,"url":null,"abstract":"Introduction: This retrospective cohort study compares in-centre haemodialysis (ICHD) patients’ outcomes between the 1st and 2nd waves of the COVID-19 pandemic in England, Wales, and Northern Ireland. Methods: All people aged ≥18 years receiving ICHD at 31 December 2019, who were still alive and not in receipt of a kidney transplant at 1 March and who had a positive polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 31 January 2021, were included. The COVID-19 infections were split into two “waves”: wave 1 from March to August 2020 and wave 2 from September 2020 to January 2021. Cumulative incidence of COVID-19, multivariable Cox models for risk of positivity, median, and 95% credible interval of reproduction number in dialysis units were calculated separately for wave 1 and wave 2. Survival and hazard ratios for mortality were described with age- and sex-adjusted Kaplan-Meier plots and multivariable Cox proportional models. Results: 4,408 ICHD patients had COVID-19 during the study period. Unadjusted survival at 28 days was similar in both waves (wave 1 75.6% [95% confidence interval [CI]: 73.7–77.5], wave 2 76.3% [95% CI 74.3–78.2]), but death occurred more rapidly after detected infection in wave 1. Long vintage treatment and not being on the transplant waiting list were associated with higher mortality in both waves. Conclusions: Risk of death of patients on ICHD treatment with COVID-19 remained unchanged between the first and second outbreaks. This highlights that this vulnerable patient group needs to be prioritized for interventions to prevent severe COVID-19, including vaccination, and the implementation of measures to reduce the risk of transmission alone is not sufficient.","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"22 1","pages":"1 - 12"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis\",\"authors\":\"M. Savino, S. Santhakumaran, C. Currie, B. Onggo, Katharine M Evans, J. Medcalf, D. Nitsch, R. Steenkamp\",\"doi\":\"10.1159/000523731\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: This retrospective cohort study compares in-centre haemodialysis (ICHD) patients’ outcomes between the 1st and 2nd waves of the COVID-19 pandemic in England, Wales, and Northern Ireland. Methods: All people aged ≥18 years receiving ICHD at 31 December 2019, who were still alive and not in receipt of a kidney transplant at 1 March and who had a positive polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 31 January 2021, were included. The COVID-19 infections were split into two “waves”: wave 1 from March to August 2020 and wave 2 from September 2020 to January 2021. Cumulative incidence of COVID-19, multivariable Cox models for risk of positivity, median, and 95% credible interval of reproduction number in dialysis units were calculated separately for wave 1 and wave 2. Survival and hazard ratios for mortality were described with age- and sex-adjusted Kaplan-Meier plots and multivariable Cox proportional models. Results: 4,408 ICHD patients had COVID-19 during the study period. Unadjusted survival at 28 days was similar in both waves (wave 1 75.6% [95% confidence interval [CI]: 73.7–77.5], wave 2 76.3% [95% CI 74.3–78.2]), but death occurred more rapidly after detected infection in wave 1. Long vintage treatment and not being on the transplant waiting list were associated with higher mortality in both waves. Conclusions: Risk of death of patients on ICHD treatment with COVID-19 remained unchanged between the first and second outbreaks. This highlights that this vulnerable patient group needs to be prioritized for interventions to prevent severe COVID-19, including vaccination, and the implementation of measures to reduce the risk of transmission alone is not sufficient.\",\"PeriodicalId\":19094,\"journal\":{\"name\":\"Nephron Clinical Practice\",\"volume\":\"22 1\",\"pages\":\"1 - 12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephron Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000523731\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephron Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000523731","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

摘要

本回顾性队列研究比较了英格兰、威尔士和北爱尔兰COVID-19大流行第一波和第二波期间中心血液透析(ICHD)患者的结果。方法:纳入所有在2019年12月31日接受ICHD的年龄≥18岁、在3月1日仍活着且未接受肾移植、在2020年3月1日至2021年1月31日期间SARS-CoV-2聚合酶链反应试验阳性的患者。新冠肺炎感染分为两波:第一波从2020年3月到8月,第二波从2020年9月到2021年1月。分别计算第1波和第2波的累积COVID-19发病率、阳性风险的多变量Cox模型、透析单位繁殖数的中位数和95%可信区间。生存率和死亡率的风险比采用年龄和性别调整后的Kaplan-Meier图和多变量Cox比例模型进行描述。结果:4408例ICHD患者在研究期间感染了COVID-19。两波28天的未调整生存率相似(第1波75.6%[95%可信区间[CI]: 73.7-77.5],第2波76.3%[95%可信区间[CI]: 74.3-78.2]),但在第1波检测到感染后,死亡发生得更快。在这两种情况下,长期的治疗和不在移植等待名单上与较高的死亡率有关。结论:在第一次和第二次疫情之间,接受ICHD治疗的COVID-19患者的死亡风险保持不变。这突出表明,这一弱势患者群体需要优先采取干预措施,以预防严重的COVID-19,包括接种疫苗,而仅采取措施降低传播风险是不够的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis
Introduction: This retrospective cohort study compares in-centre haemodialysis (ICHD) patients’ outcomes between the 1st and 2nd waves of the COVID-19 pandemic in England, Wales, and Northern Ireland. Methods: All people aged ≥18 years receiving ICHD at 31 December 2019, who were still alive and not in receipt of a kidney transplant at 1 March and who had a positive polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 31 January 2021, were included. The COVID-19 infections were split into two “waves”: wave 1 from March to August 2020 and wave 2 from September 2020 to January 2021. Cumulative incidence of COVID-19, multivariable Cox models for risk of positivity, median, and 95% credible interval of reproduction number in dialysis units were calculated separately for wave 1 and wave 2. Survival and hazard ratios for mortality were described with age- and sex-adjusted Kaplan-Meier plots and multivariable Cox proportional models. Results: 4,408 ICHD patients had COVID-19 during the study period. Unadjusted survival at 28 days was similar in both waves (wave 1 75.6% [95% confidence interval [CI]: 73.7–77.5], wave 2 76.3% [95% CI 74.3–78.2]), but death occurred more rapidly after detected infection in wave 1. Long vintage treatment and not being on the transplant waiting list were associated with higher mortality in both waves. Conclusions: Risk of death of patients on ICHD treatment with COVID-19 remained unchanged between the first and second outbreaks. This highlights that this vulnerable patient group needs to be prioritized for interventions to prevent severe COVID-19, including vaccination, and the implementation of measures to reduce the risk of transmission alone is not sufficient.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nephron Clinical Practice
Nephron Clinical Practice 医学-泌尿学与肾脏学
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信